EcoR1 Capital is a biotech-focused investment advisory firm that partners with bold entrepreneurs to advance therapeutic innovation and develop new medicines. The firm invests in companies at all stages of research and development, from early-stage ventures to public companies, with a primary focus on the biotechnology sector.
EcoR1 Capital's portfolio includes notable companies such as Editas Medicine, Intellia Therapeutics, and Sage Therapeutics. The firm's investment strategy emphasizes long-term partnerships and propelling scientific discovery. EcoR1 Capital provides value to its portfolio companies through its deep understanding of biological and chemical breakthroughs, supporting pioneering advancements in the biotech industry.
EcoR1 Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments74
Current Portfolio Count51
Total Portfolio Exits7
Top Investment Stages
Series B22 (31.9%)
Post Ipo Equity18 (26.1%)
Series A14 (20.3%)
Series C12 (17.4%)
Private Equity3 (4.3%)
Stage Mix
Series B 32%Post Ipo Equity 26%Series A 20%Series C 17%Private Equity 4%
Concentration shown as share of disclosed investments by stage.
EcoR1 Capital - Classification
- Also Known As
- Ecor1 Capital, LLC
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6720Investment Offices
- 6722Management Investment Offices, Open-end
Show 2 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- SIC
- 6000Depository Institutions